Abstracts tagged "Systemic lupus erythematosus (SLE)"

Abstract Number: L10 • ACR Convergence 2020
Targeting Plasmacytoid Dendritic Cells Improves Cutaneous Lupus Erythematosus Skin Lesions and Reduces Type I Interferon Levels: Results of a Phase 1 Study of VIB7734
Victoria Werth¹, Jodi Karnell², William Rees², Nanette Mittereder³, Li Yan², Yanping Wu³, Jorn Drappa², Gabor Illei² and John Ratchford², ¹University of Pennsylvania, Philadelphia, PA, ²Viela Bio, Gaithersburg, MD, ³Viela Bio, Gaithersburg
Background/Purpose: Plasmacytoid dendritic cells (pDCs) secrete large amounts of type I interferon (IFN) and other cytokines upon activation. pDCs migrate to sites of active disease…
Abstract Number: 0248 • ACR Convergence 2020
Assessment of Lupus Knowledge Through Creation of the Lupus Knowledge Assessment Test (LKAT)
Mithu Maheswaranathan¹, Amanda Eudy¹, Jayanth Doss¹, Rebecca Sadun¹, Lisa Criscione-Schreiber², Kai Sun¹, Stacy Bailey³, S. Nicole Hastings¹, Megan Clowse⁴ and Jennifer Rogers⁵, ¹Duke University, Durham, NC, ²Duke University School of Medicine, Durham, NC, ³Northwestern University, Chapel Hill, NC, ⁴Duke University, Chapel Hill, NC, ⁵Duke, Durham, NC
Background/Purpose: Systemic lupus erythematosus (SLE) is an inherently complex disease to manage with heterogenous clinical manifestations and complicated medication regimens. The complexity of lupus self-management…
Abstract Number: 0265 • ACR Convergence 2020
Evaluation of the Lupus Foundation of America-Rapid Evaluation of Activity in Lupus as a Measure of Systemic Lupus Erythematosus (SLE) Disease Activity from the Clinician and the Patient Perspective: Experience from an Italian Cohort
Elena Elefante¹, Chiara Tani², Viola Signorini², Virginia Poli², Chiara Stagnaro², Alice Parma², Dina Zucchi², Linda Carli², Francesco Ferro², Anca Askanase³ and Marta Mosca², ¹Rheumatology Unit, Department of Clinical and Experimental Medicine, University of Pisa; Department of Medical Biotechnology, University of Siena, Pisa, Italy, ²Rheumatology Unit, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy, ³Columbia University College of Physicians & Surgeons, New York, NY
Background/Purpose: Multiple indices are available to measure disease activity in SLE patients, but are often considered too complex and time consuming for use in routine…
Abstract Number: 0281 • ACR Convergence 2020
ANCA in SLE: Prevalence and Predictor Factors
Reza Mirza¹, Murray Urowitz², Jiandong Su³ and Dafna Gladman⁴, ¹University of Toronto, Toronto, ON, Canada, ²University Health Network, University of Toronto, Toronto, ON, Canada, ³University of Toronto Lupus Clinic, Centre for Prognosis Studies in Rheumatic Diseases, Toronto Western Hospital, University Health Network, Toronto, ON, Canada, ⁴Krembil Research Institute, Toronto Western Hospital, Toronto, ON, Canada
Background/Purpose: SLE is a systemic autoimmune disease notable for the ability to affect nearly every tissue, and is associated with a breadth of auto-antibodies. Anti-neutrophilic…
Abstract Number: 0299 • ACR Convergence 2020
The Minor Protective Allele at rs1876453 Is Associated with Increased Age of Onset of Systemic Lupus Erythematosus
Ani Oganesyan¹, Jennifer Kelly², Stuart Glenn², Adam Adler², Adrienne Williams³, Mary Comeau⁴, Julia Ziegler⁵, Miranda Marion⁵, Marta Alarcón-Riquelme⁶, Graciela Alarcón⁷, Juan-Manuel Anaya⁸, Sang-Cheol Bae⁹, Dam Kim⁹, Lee Hye-Soon⁹, Lindsey Criswell¹⁰, Barry Freedman¹¹, Gary Gilkeson¹², Joel Guthridge¹³, Chaim Jacob¹⁴, Judith James¹⁵, Diane Kamen¹⁶, Joan Merrill¹⁷, Kathy Moser Silvis¹⁸, Timothy Niewold¹⁹, Michelle Petri²⁰, Rosalind Ramsey-Goldman²¹, John Reveille²², Hal Scofield²³, Anne Stevens²⁴, Luis Vilá²⁵, Timothy Vyse²⁶, Kenneth Kaufman²⁷, John Harley²⁸, Carl Langefeld⁵, Patrick Gaffney², Elizabeth Brown²⁹, Jeffrey Edberg⁷, Robert Kimberly⁷, Betty Tsao¹², Daniela Ulgiati³⁰, Kenneth Jones³¹ and Susan Boackle³², ¹Division of Rheumatology, University of Colorado School of Medicine, Aurora, CO, ²Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, ³Department of Biostatistical Sciences and Center for Public Health Genomics Wake Forest School of Medicine, Winston-Salem,, NC, ⁴Department of Biostatistical Sciences and Center for Public Health Genomics, Wake Forest School of Medicine; MC Analytics, Winston-Salem, NC, ⁵Department of Biostatistical Sciences and Center for Public Health Genomics, Wake Forest School of Medicine, Winston-Salem, NC, ⁶Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation;Centro Pfizer-Universidad de Granada-Junta de Andalucía de Genómica e Investigación Oncológica, Granada (GENYO), Granada, Spain, ⁷Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, ⁸Center for Autoimmune Diseases Research (CREA), Universidad del Rosario, Bogotá, Colombia, ⁹Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, Republic of Korea, ¹⁰Rosalind Russell/Ephraim P. Engleman Rheumatology Research Center, University of California San Francisco, San Francisco, CA, ¹¹Department of Internal Medicine, Wake Forest School of Medicine, Winston-Salem,, NC, ¹²Division of Rheumatology, Medical University of South Carolina, Charleston, SC, ¹³Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation, Oaklahoma, OK, ¹⁴Department of Medicine, University of Southern California, Los Angeles, CA, ¹⁵Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation;Department of Pathology, University of Oklahoma Health Sciences Center;Department of Medicine, University of Oklahoma Health Sciences Center, Edmond, OK, ¹⁶Medical University of South Carolina, Charleston, SC, ¹⁷Department of Clinical Pharmacology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ¹⁸Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation; Department of Pathology, University of Oklahoma Health Sciences Center, Oklahoma City, OK, ¹⁹Colton Center for Autoimmunity, NYU School of Medicine, New York, NY, ²⁰Johns Hopkins University School of Medicine, Baltimore, ²¹Division of Rheumatology, Northwestern University Feinberg School of Medicine, Chicago, IL, ²²Department of Internal Medicine, University of Texas, Houston, TX, ²³Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation; Department of Medicine, University of Oklahoma Health Sciences Center; US Department of Veterans Affairs Medical Center, Charleston, SD, ²⁴Janssen Pharmaceuticals, Spring House, PA, ²⁵Division of Rheumatology, Department of Medicine, University of Puerto Rico Medical Sciences Campus, San Juan, Puerto Rico, ²⁶Division of Genetics and Molecular Medicine and Immunology, King’s College, London, United Kingdom, ²⁷Cincinnati Children’s Hospital Medical Center;US Department of Veterans Affairs Medical Center, Cincinnati, OH, ²⁸Cincinnati Children's Hospital Medical Center/Univ of Cincinnati College of Medicine, Cincinnati, OH, ²⁹Department of Pathology, University of Alabama at Birmingham, Birmingham, AL, ³⁰School of Pathology and Laboratory Medicine, Centre for Genetic Origins of Health and Disease, The University of Western Australia, Crawley, Australia, ³¹Harold Hamm Diabetes Center, University of Oklahoma Health Science Center, Oklahoma City, OK, ³²Division of Rheumatology, University of Colorado School of Medicine; Denver Veterans Affairs Medical Center, Aurora, CO
Background/Purpose: Systemic lupus erythematosus (SLE) is a clinically heterogenous autoimmune disease characterized by autoantibody- and complement-mediated inflammatory damage to multiple organ systems. We previously showed…
Abstract Number: 0494 • ACR Convergence 2020
Genetic-epigenetic Interaction and the Relationship Between DNA Methylation Patterns and Disease Activity in a Longitudinal Cohort of Lupus Patients
Patrick Coit¹, Lourdes Ortiz-Fernandez², Emily Lewis³, W. Joseph McCune³, Kathleen Maksimowicz-McKinnon⁴ and Amr Sawalha², ¹University of Pittsburgh and University of Michigan, Pittsburgh, PA, ²University of Pittsburgh, Pittsburgh, PA, ³University of Michigan, Ann Arbor, MI, ⁴Henry Ford Hospital, Detroit
Background/Purpose: Genetic factors and epigenetic dysregulation are implicated in the pathogenesis of lupus. We performed a longitudinal analysis of DNA methylation in lupus patients for…
Abstract Number: 0612 • ACR Convergence 2020
Differences in 30-Day Rehospitalization Risk and Predictors by Age Group Among Patients with Lupus in Medicare
Maria Schletzbaum¹, Yi Chen², Ann Sheehy³, Farah Kaiksow³, Ryan Powell⁴, Andrea Gilmore-Bykovskyi⁵, Amy Kind⁶ and Christie Bartels⁷, ¹University of Wisconsin-Madison School of Medicine and Public Health, Department of Population Health Sciences, Madison, WI, ²University of Wisconsin School of Medicine and Public Health, Department of Biostatistics and Medical Informatics, Madison, WI, ³University of Wisconsin School of Medicine and Public Health, Department of Medicine, Hospital Medicine Division, Madison, WI, ⁴University of Wisconsin School of Medicine and Public Health, Department of Medicine, Geriatrics Division, Madison, WI, ⁵University of Wisconsin - Madison, School of Nursing, Madison, WI, ⁶University of Wisconsin-Madison School of Medicine and Public Health, Department of Medicine, Health Services and Care Research Program, Geriatrics Division, Madison, WI, ⁷University of Wisconsin School of Medicine and Public Health, Department of Medicine, Division of Rheumatology, Madison, WI
Background/Purpose: Although our recent research demonstrates that young adult Medicare beneficiaries (age 18-35) with lupus (SLE) have higher risk of 30-day rehospitalization, predictors specific to…
Abstract Number: 0848 • ACR Convergence 2020
Delineation of a Proinflammatory Cytokine Profile Targeted by Janus Kinase 1/2 Inhibition Using Baricitinib in a Phase 2 Systemic Lupus Erythematosus Trial
Thomas Dörner¹, Yoshiya Tanaka², Michelle Petri³, Josef Smolen⁴, Daniel Wallace⁵, Brenda Crowe⁶, Ernst Dow⁶, Richard Higgs⁶, Guilherme Rocha⁶, Robert Benschop⁶, Maria Silk⁶, Stephanie de Bono⁶, Robert Hoffman⁶ and Damiano Fantini⁶, ¹DRFZ and Charité University Hospitals, Berlin, Germany, ²The First Department of Internal Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan, ³Johns Hopkins University School of Medicine, Timonium, MD, ⁴Division of Rheumatology, Department of Medicine III, Medical University of Vienna, Vienna, Austria, ⁵Cedars-Sinai Medical Center/UCLA, Los Angeles, CA, ⁶Eli Lilly and Company, Indianapolis, IN
Background/Purpose: Given the unmet clinical needs in systemic lupus erythematosus (SLE), including poor disease control and drug toxicities, new therapies are needed. In a phase…
Abstract Number: 0866 • ACR Convergence 2020
Identifying an SLE Patient Cluster with Greater Treatment Effect: Immune Cell Deconvolution of Gene Expression in Two Atacicept Phase II Studies
Joan Merrill¹, Matthew Studham², Eric Morand³, Aida Aydemir², Cristina Vazquez Mateo², Alex Rolfe², Amy Kao² and Robert Townsend², ¹Oklahoma Medical Research Foundation, Oklahoma City, OK, ²EMD Serono (a business of Merck KGaA, Darmstadt, Germany), Billerica, MA, ³Medicine, School of Clinical Sciences at Monash Health, Monash University, Melbourne, Australia
Background/Purpose: Atacicept, a dual inhibitor of the B lymphocyte stimulator and a proliferation-inducing ligand (APRIL), has been associated with a reduction of flares in the…
Abstract Number: 0983 • ACR Convergence 2020
Outcomes Following Antimalarial Withdrawal in Patients with Quiescent Systemic Lupus Erythematosus
Danae Papachristos¹, Dafna Gladman², Jiandong Su³ and Murray Urowitz⁴, ¹University Health Network, Toronto, ON, Canada, ²Krembil Research Institute, Toronto Western Hospital, Toronto, ON, Canada, ³University of Toronto Lupus Clinic, Centre for Prognosis Studies in Rheumatic Diseases, Toronto Western Hospital, University Health Network, Toronto, ON, Canada, ⁴University Health Network, University of Toronto, Toronto, ON, Canada
Background/Purpose: Antimalarial medications (AMs) are central to the management of SLE, affording numerous clinical benefits including the reduction of disease flare. However, little is known…
Abstract Number: 1026 • ACR Convergence 2020
The Incidence, Mortality, and Economic Burden of Potentially Preventable Infections in Systemic Lupus Erythematosus Patients
Estefania Gauto-Mariotti¹, Soumyasri Kambhatla² and Augustine Manadan³, ¹John H. Stroger Jr. Hospital of Cook County, Chicago, IL, ²John H Stroger Hospital of Cook County, Riverside, IL, ³Rush University Medical Center, Chicago, IL
Background/Purpose: Streptococcus pneumoniae, Herpes zoster, and influenza infections are common and potentially preventable causes of morbidity and mortality. Vaccinations have been shown to reduce infection…
Abstract Number: 1264 • ACR Convergence 2020
Mortality in Patients with Systemic Lupus Erythematosus and Neuropsychiatric Symptoms
Rory Monahan¹, Rolf Fronczek¹, Jeroen Eikenboom¹, Huub Middelkoop¹, Liesbeth Beaart-van de Voorde¹, Gisela Terwindt¹, Nic van der Wee¹, Frits Rosendaal¹, Thomas Huizinga¹, Margreet Kloppenburg¹ and Margreet Steup-Beekman¹, ¹Leiden University Medical Center, Leiden, Netherlands
Background/Purpose: Little is known about mortality in patients with systemic lupus erythematosus (SLE) presenting with neuropsychiatric (NP) symptoms. We aimed to evaluate all-cause and cause-specific…
Abstract Number: 1280 • ACR Convergence 2020
COVID-19 Infections May Increase the Risk of SLE Flares
Leila Khalili¹, Yevgeniya Gartshteyn², Nancyanne Schmidt³, Teja Kapoor⁴, Laura Geraldino-Pardilla⁵ and Anca Askanase³, ¹Columbia University Medical Center, New York, NY, ²Columbia University College of Physicians and Surgeons, Glen Rock, NJ, ³Columbia University College of Physicians and Surgeons, New York, NY, ⁴Columbia University College of Physicians and Surgeons, Leonia, NJ, ⁵Division of Rheumatology, Columbia University Vagelos College of Physicians and Surgeons, New York
Background/Purpose: COVID-19 has overwhelmed the healthcare systems in New York City. Initial data from the Columbia Lupus Cohort suggests that 4% of patients with systemic…
Abstract Number: 1296 • ACR Convergence 2020
Associations of Metabolic Syndrome and Adipokines in SLE
Diane Apostolopoulos¹, Fabien Vincent², Rachel Koelmeyer², Alberta Hoi¹ and Eric Morand³, ¹Monash University, Melbourne, Victoria, Australia, ²Monash University, Clayton, Victoria, Australia, ³Medicine, School of Clinical Sciences at Monash Health, Monash University, Melbourne, Australia
Background/Purpose: Metabolic syndrome (MetS) is a chronic pro-inflammatory and pro-thrombotic state associated with increased atherosclerosis, cardiovascular events and type 2 diabetes. It is diagnosed in…
Abstract Number: 1501 • ACR Convergence 2020
Obstetrical Outcome and Thromboses in a Multicentric Cohort of Antiphospholipid Syndrome (APS) Patients with Severe Preeclampsia: An Analysis of APS Classification Criteria
Maddalena Larosa¹, Nathalie Morel², Meriem Belhocine³, Amelia Ruffatti⁴, Nicolas Martin Silva⁵, Romain Paule⁶, Luc Mouthon⁷, Michel Dreyfus⁸, Jean-Charles Piette⁹, Odile Souchaud-Debouverie¹⁰, Catherine Deneux-Tharaux¹¹, Vassilis Tsatsaris¹², Emmanuelle Pannier Metzger¹³, Gaëlle Guettrot-Imbert¹⁴, Veronique Le Guern¹⁵, Andrea Doria¹⁶ and Nathalie Costedoat-Chalumeau¹⁷, ¹Rheumatology Unit-Department of Medicine-University of Padova, Italy, Padova, Veneto, Italy, ²AP-HP, université René-Descartes Paris V, hôpital Cochin, centre de référence maladies auto-immunes et systémiques rares, pôle médecine, service de médecine interne, Paris, France., Paris, Ile-de-France, France, ³Hôpital Sacré-Coeur de Montréal , Montréal, Montreal, QC, Canada, ⁴Department of Medicine, University of Padova, Padova, Veneto, Italy, ⁵Centre Hospitalier et Universitaire de Caen, Caen, France, ⁶Foch Hospital, Paris, France, ⁷Hopital Cochin - Paris University, Paris, France, ⁸CHU de Caen, Caen, France, ⁹Department of Internal Medicine, Hôpital Pitié-Salpêtrière, Paris, France, Paris, France, ¹⁰CENTRE HOSPITALIER UNIVERSITAIRE LA MILETRIE, poitiers, France, ¹¹INSERM U1153, Obstetrical, Perinatal and Pediatric Epidemiology Research Team, Center for Epidemiology and Statistics Sorbonne Paris Cité , Paris Descartes University , Paris , France, Paris, France, ¹²Maternité Port-Royal,Hôpital Cochin, Paris, France, Paris, France, ¹³Maternité Port-Royal,Hôpital Cochin, Paris, France, ¹⁴Médecine Interne,Hôpital Cochin, paris, France, ¹⁵Médecine Interne,Hôpital Cochin, Paris, France, Paris, France, ¹⁶University of Padua, Padua, Italy, ¹⁷APHP, Université de Paris, Paris, France
Background/Purpose: According to APS classification criteria1, clinical manifestations of antiphospholipid syndrome (APS) consist in thrombotic and obstetric events, including severe preeclampsia (PE). Because little is…

1
2
3
…
43
Next Page »